LINLINE MEDICAL SYSTEMS
A recent study published in the Journal of Wound Care (UK) has shed light on a revolutionary approach to diabetic foot care that promises hope and relief for millions worldwide.
LONDON, UK / ACCESSWIRE / October 27, 2023 / LINLINE MEDICAL SYSTEMS, based in Riga, Latvia, has demonstrated the remarkable effectiveness of its distinctive RecoSMA laser technology in treating chronic wounds. The recent study, "Spatially modulated erbium YAG laser as a treatment for diabetic ulcer", published in the Journal of Wound Care (UK), was conducted using a MULTILINE laser system produced by the company.
Chronic ulcers treatment: a two-step approach
The study, conducted by a team of esteemed researchers (Prof. Smita P. Andurkar, Dr. Ram M. Chilgar), aimed to address the pressing issue of diabetic foot complications, which affect a substantial portion of the global population. According to the International Diabetes Federation, an alarming 463 million people are currently diagnosed with diabetes, projected to surge by 50% within the next three decades.
Diabetic foot ulcers are one of the most debilitating consequences of diabetes, often leading to severe complications, including amputations and significant financial burdens on patients and healthcare systems.
The dire reality is that individuals with diabetes face a 15-fold higher likelihood of undergoing lower extremity amputations than those without diabetes. Statistics indicate that, globally, a major amputation (above or below the knee) is performed on a person with diabetes every 20-30 seconds.
In this landmark study, researchers explored the use of a novel laser treatment for diabetic foot ulcers designed to revolutionize how we approach this chronic problem. By employing the spatially modulated high-power Erbium YAG (Er-YAG) laser technology, the team aimed to tackle diabetic foot ulcers in a two-step process that involved laser wound debridement and deep tissue biostimulation using the RecoSMA technology (implemented in "MULTILINE" laser system, produced by LINLINE MS).
The study included 59 patients with hard-to-heal diabetic foot ulcers and documented remarkable results.
The mean wound surface area at baseline was 25.7 cm2. The average number of laser treatment sessions required was 4.41, ranging from 1-11. The ulcers gradually reduced in size with each session, ultimately leading to complete wound closure in 100% of cases.
Laser treatment made it possible to clear wounds of necrotic tissue and microbial bioburden without damaging viable tissue. The procedures were painless on an outpatient basis.
The RecoSMA laser operates by activating the body's innate healing processes, fostering neovascularization, and expediting tissue regeneration. This mechanism facilitates wound healing through re-epithelialization originating from the wound's edges and granulation emerging from the wound bed's depths, all without the formation of fibrosis. This unique approach promotes scar-free and unimpeded wound healing, a pivotal factor in effective rehabilitation.
The impact of this research is profound. It suggests a potential paradigm shift in the way we approach diabetic foot ulcers, offering a beacon of hope for those affected by this debilitating condition. By harnessing the power of innovative laser therapy, we have the opportunity to enhance the quality of life for individuals suffering from diabetic foot complications and to reduce the economic strain on healthcare systems.
For more details about the technology, please visit the website:
https://www.non-healing-wound.care/
The link to the study: https://doi.org/10.12968/jowc.2023.32.Sup10a.S21
About us: LINLINE Medical Systems SIA (Riga, Latvia) is a world-leading company specialising in developing and manufacturing advanced medical lasers designed to treat various conditions in surgery, endoscopy, dermatology, gynaecology, wound healing and aesthetic medicine.
Company's website: https://linline-ms.com/.
Contact Information
Alex Troshkin
Co-founder, board member
at@linline-ms.com
+37122453227
Related Files
chilgar-andurkar-2023-spatially-modulated-erbium-yag-laser-as-a-treatment-for-diabetic-ulcer (1).pdf
SOURCE: LINLINE MEDICAL SYSTEMS
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/796785/groundbreaking-study-reveals-the-effectiveness-of-new-recosma-laser-treatment-for-diabetic-foot
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Movella Holdings Inc. Announces Completion of Corporate Restructuring6.5.2025 10:30:00 CEST | Press release
LOS ANGELES, CA / ACCESS Newswire / May 6, 2025 / Movella Holdings Inc. (the "Company") today announced the completion of a restructuring transaction involving its wholly-owned subsidiary, Movella Inc. ("Movella"), and its existing secured lenders. In connection with the transaction, Movella, the Company, certain of its subsidiaries, FP Credit Partners II AIV, L.P. and FP Credit Partners Phoenix II AIV, L.P. (the "FP Noteholders"), and FP Credit Partners II, L.P. and FP Credit Partners Phoenix II, L.P. (the "FP Shareholders") entered into a Restructuring Agreement (the "Restructuring Agreement") in response to continuing events of default under the Note Purchase Agreement, dated as of November 14, 2022 (the "Note Purchase Agreement"), pursuant to which Movella had previously issued secured promissory notes to the FP Noteholders with the Company as a guarantor of the secured promissory notes. Pursuant to the Restructuring Agreement and related transactions (the "Restructuring Transactio
Loar Holdings Inc. Announces Date and Time for First Quarter 2025 Earnings Conference Call6.5.2025 08:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 6, 2025 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2025 earnings before the market opens on Tuesday, May 13, 2025. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations
Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D6.5.2025 08:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / May 6, 2025 / A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, and critical systemic barriers impeding the global fight against hepatitis delta. Also known as hepatitis D, hepatitis delta is a severe liver disease affecting an estimated 12 million people worldwide. It occurs in people living with hepatitis B, leads to faster disease progression, and significantly increases the risk of liver cancer and death. The Hepatitis Delta Global Landscape Survey collected responses from 583 individuals across 102 countries, providing the most comprehensive picture to date of global stakeholder perspectives on awareness, testing, and treatment access around hepatitis delta. Key Findings: There are pronounced regional variations in reported availability and accessibility of hepatitis delta testing and treatment. Even where hepatitis delta testing and treatment are reported to be available, acces
Camino Announces Exploration Results at Los Chapitos and Further Exploration Plans in Peru6.5.2025 06:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 6, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) (WKN: A116E1) ("Camino" or the "Company") is pleased to announce exploration results at its Copper-Silver stratabound Los Chapitos copper project ("Los Chapitos" or the "Project"), including drilling and additional mapping, trenching, and sampling along both the La Estancia and Diva copper mineralized trends. The Company is targeting large-scale disseminated manto-type copper-silver mineralization to support resource delineation studies at Los Chapitos. Camino and its partner Nittetsu Mining Co., Ltd. ("Nittetsu") plan to commence the next phase of drilling in the second half of 2025. The Los Chapitos copper project is located near the coastal city of Chala in the department of Arequipa in Peru. Juan Carlos Castelli, Consulting Geologist from Chile, said "the Los Chapitos property is inside the northern continuation of the metallogenic Cu-Ag belt defined in Northern Chile, with operat
OMP Achieves Top Two Rankings in Four Use Cases in the 2025 Gartner Critical Capabilities for Supply Chain Planning Solutions Report6.5.2025 05:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / May 6, 2025 / OMP, a global leader in supply chain planning solutions, has achieved four second-highest scores across five Use Cases, evaluated in the 2025 Gartner® Critical Capabilities for Supply Chain Planning Solutions report. This report, a companion to the Gartner Magic Quadrant™, assesses the vendors of the SCP solutions evaluated in this research. This recognition follows OMP's recent position as highest on the Ability to Execute axis in the 2025 Gartner Magic Quadrant for Supply Chain Planning Solutions - marking the tenth consecutive time OMP is named a Leader. Consistent strength across real-world planning challenges The Critical Capabilities report evaluates 20 vendors on 15 key capabilities across five SCP Use Cases. We believe OMP's scores, particularly in supply planning, decision/plan alignment, and the breadth of resource types, demonstrate its strong performance in these critical areas. "Supply chains today need real solutions that de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom